Hospital
MCHS Hospitals INC
MCHS Hospitals INC was paid $45.31M by Medicaid between Jan 2018 and Dec 2024, across 619 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 13% of everything it billed.
33Billing provider infoMCHS HOSPITALS INC
MARSHFIELD, WI 54449
MARSHFIELD, WI 54449
33aNPI1942749387assigned 02/17/2017
33bProvider typeGeneral Acute Care Hospital
28Total paid$45.31M
24GClaims1,615,608
24DCodes billed619
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Wisconsin
Rank by total paid#5 of 60
Median peer was paid$2.90M
This provider vs. median16×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MUNSON, JOLYN controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 164,170 | $4.95M | |
| 2019 | 245,483 | $7.33M | |
| 2020 | 221,159 | $5.73M | |
| 2021 | 204,486 | $5.78M | |
| 2022 | 265,032 | $6.31M | |
| 2023 | 277,896 | $7.92M | |
| 2024incomplete | 237,382 | $7.29M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 13% | 85,118 | 70,546 | $5.96M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 9.9% | 69,076 | 57,561 | $4.46M |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 4.2% | 22,779 | 19,573 | $1.89M |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.4% | 14,133 | 7,760 | $1.52M |
| T2023 | Targeted case management; per month | 3.1% | 3,839 | 3,561 | $1.41M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 2.2% | 16,533 | 13,917 | $991K |
| 99244 | Office or other outpatient consultation, moderate to high complexity | 1.7% | 10,773 | 9,404 | $789K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.5% | 13,080 | 11,297 | $667K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 1.4% | 13,964 | 11,487 | $646K |
| 80053 | Comprehensive metabolic panel | 1.4% | 36,689 | 28,869 | $643K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.3% | 2,700 | 2,422 | $600K |
| 90834 | Psychotherapy session, about 45 minutesPsychotherapy, 45 minutes with patient | 1.2% | 9,910 | 6,690 | $532K |
607 more codes
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 1.2% | 7,800 | $527K |
| 99243 | 1.2% | 7,194 | $525K | |
| 99203 | Doctor's office visit, new patient (routine) | 1.1% | 8,450 | $492K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 1.1% | 7,142 | $489K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 6,794 | $436K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 3,469 | $414K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 6,202 | $405K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 48,417 | $390K |
| 99245 | <1% | 4,893 | $387K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 5,253 | $380K |
| 96139 | <1% | 3,284 | $379K | |
| 99285 | Emergency room visit (most serious) | <1% | 9,408 | $378K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 7,621 | $375K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 13,356 | $363K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 6,646 | $355K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 61,165 | $347K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 23,873 | $336K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,646 | $332K |
| 96138 | <1% | 3,442 | $326K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 4,927 | $317K |
| 96133 | <1% | 2,530 | $304K | |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 2,649 | $296K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 3,416 | $290K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 1,470 | $290K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 3,744 | $287K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 4,768 | $286K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 4,342 | $280K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 5,121 | $277K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,649 | $276K |
| 80061 | Lipid panel | <1% | 14,062 | $271K |
| 59025 | Fetal non-stress test | <1% | 3,383 | $266K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 4,651 | $261K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 4,133 | $257K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 4,959 | $248K |
| 96132 | <1% | 2,592 | $247K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 4,228 | $230K |
| 99205 | Prolong outpt/office vis | <1% | 3,231 | $216K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 3,780 | $212K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 12,087 | $209K |
| 81514 | <1% | 1,879 | $208K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 4,706 | $196K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 704 | $193K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,976 | $187K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 5,969 | $182K |
| 82728 | <1% | 8,293 | $170K | |
| 81001 | <1% | 26,567 | $164K | |
| 92015 | Determination of refractive state | <1% | 7,068 | $162K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 772 | $158K |
| 87081 | <1% | 4,774 | $157K | |
| 90670 | <1% | 4,525 | $144K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,004 | $143K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,859 | $140K |
| 81025 | <1% | 9,073 | $139K | |
| 96415 | <1% | 1,585 | $135K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 5,172 | $134K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,452 | $132K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 1,328 | $124K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,943 | $123K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 13,706 | $122K |
| 95811 | <1% | 799 | $120K | |
| 96130 | <1% | 1,239 | $119K | |
| 82962 | <1% | 17,327 | $117K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 2,435 | $116K |
| 76770 | <1% | 1,748 | $115K | |
| 99242 | <1% | 1,656 | $112K | |
| 88142 | <1% | 4,415 | $111K | |
| 76801 | <1% | 2,038 | $110K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,103 | $108K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,165 | $106K |
| 87186 | <1% | 4,995 | $104K | |
| 96131 | <1% | 906 | $103K | |
| 85610 | <1% | 9,700 | $103K | |
| 90674 | <1% | 6,580 | $102K | |
| 82950 | <1% | 2,140 | $100K | |
| 97597 | <1% | 2,947 | $98K | |
| 83655 | <1% | 2,590 | $98K | |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 1,720 | $97K |
| G0378 | Hospital observation service, per hour | <1% | 8,529 | $96K |
| 85027 | <1% | 10,734 | $94K | |
| 84484 | <1% | 11,783 | $90K | |
| 20610 | <1% | 1,542 | $86K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 2,200 | $84K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 1,033 | $84K |
| 86803 | <1% | 3,750 | $84K | |
| 90651 | <1% | 2,238 | $84K | |
| 90715 | <1% | 3,804 | $80K | |
| 99001 | <1% | 2,400 | $79K | |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 513 | $78K |
| 92587 | <1% | 680 | $78K | |
| 69210 | <1% | 1,887 | $76K | |
| 80050 | General health panel | <1% | 6,528 | $75K |
| 83880 | <1% | 3,008 | $74K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,291 | $74K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,161 | $74K |
| 84702 | <1% | 1,937 | $72K | |
| 87481 | <1% | 2,482 | $72K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,432 | $70K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 1,382 | $70K |
| 93296 | <1% | 3,174 | $69K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,870 | $69K |
| 96118 | <1% | 366 | $69K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 941 | $68K |
| Q5104 | Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | <1% | 214 | $65K |
| 93325 | <1% | 1,535 | $64K | |
| 96119 | <1% | 367 | $62K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 587 | $62K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,287 | $61K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 912 | $60K |
| 83970 | <1% | 1,283 | $60K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,475 | $57K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,057 | $57K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 4,258 | $56K |
| 90680 | <1% | 3,498 | $55K | |
| 96136 | <1% | 635 | $55K | |
| 81513 | <1% | 793 | $55K | |
| 64493 | <1% | 261 | $54K | |
| 82784 | <1% | 4,145 | $54K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,873 | $53K |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 1,175 | $52K |
| 86140 | <1% | 11,906 | $50K | |
| 86364 | <1% | 1,948 | $49K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,596 | $48K |
| 15275 | <1% | 344 | $47K | |
| 84439 | <1% | 5,538 | $46K | |
| Q3014 | Telehealth originating site facility fee | <1% | 5,598 | $46K |
| 90633 | <1% | 2,634 | $46K | |
| 84145 | <1% | 2,965 | $45K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 262 | $45K |
| 83516 | <1% | 1,428 | $44K | |
| 83690 | <1% | 8,680 | $44K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,268 | $42K |
| 87075 | <1% | 2,686 | $42K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 495 | $42K |
| 83735 | <1% | 9,099 | $41K | |
| 84153 | <1% | 1,470 | $40K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 632 | $40K |
| 17110 | <1% | 528 | $40K | |
| 90756 | <1% | 2,507 | $40K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,074 | $39K |
| 93976 | <1% | 1,445 | $39K | |
| 73630 | <1% | 5,597 | $39K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 743 | $38K |
| 93971 | <1% | 1,322 | $38K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 21,784 | $38K |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 2,026 | $38K |
| 86762 | <1% | 2,067 | $37K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 10,249 | $37K |
| 93320 | <1% | 384 | $37K | |
| 87070 | <1% | 3,955 | $37K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 5,672 | $37K |
| 86850 | <1% | 4,398 | $36K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 573 | $36K |
| 87634 | <1% | 717 | $35K | |
| 82248 | <1% | 2,770 | $34K | |
| 74018 | <1% | 2,810 | $34K | |
| 73610 | <1% | 3,775 | $34K | |
| 82565 | <1% | 4,262 | $34K | |
| 85018 | <1% | 6,702 | $34K | |
| 64494 | <1% | 227 | $33K | |
| 11721 | <1% | 1,500 | $33K | |
| 84703 | <1% | 2,804 | $33K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 94 | $32K |
| 82607 | <1% | 2,318 | $32K | |
| 90716 | <1% | 1,112 | $32K | |
| 87340 | <1% | 3,826 | $32K | |
| 90619 | <1% | 693 | $31K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 12,743 | $31K |
| 86780 | <1% | 3,542 | $31K | |
| 64635 | <1% | 209 | $31K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 4,645 | $30K |
| 90686 | <1% | 1,705 | $30K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,444 | $30K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 379 | $30K |
| 15271 | <1% | 183 | $29K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 80 | $29K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,758 | $29K |
| 83605 | <1% | 4,091 | $29K | |
| 82657 | <1% | 618 | $27K | |
| 82570 | <1% | 3,675 | $27K | |
| J0178 | Injection, aflibercept, 1 mg | <1% | 156 | $27K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 10,603 | $27K |
| 64636 | <1% | 222 | $27K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 40 | $26K |
| 90734 | <1% | 1,372 | $26K | |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 508 | $26K |
| 96120 | <1% | 157 | $26K | |
| 86708 | <1% | 786 | $25K | |
| 92341 | <1% | 235 | $25K | |
| 90846 | Family psychotherapy without the patient present, 50 minutes | <1% | 247 | $25K |
| 83550 | <1% | 3,633 | $25K | |
| 87506 | <1% | 119 | $25K | |
| 92340 | Fitting of spectacles, except for aphakia; monofocal | <1% | 1,394 | $24K |
| 82803 | <1% | 809 | $23K | |
| 87088 | <1% | 1,688 | $23K | |
| 85379 | <1% | 3,021 | $23K | |
| 82105 | <1% | 875 | $23K | |
| 87040 | <1% | 2,778 | $23K | |
| 94010 | <1% | 2,059 | $21K | |
| 90870 | <1% | 168 | $21K | |
| 86703 | <1% | 1,893 | $21K | |
| 87077 | <1% | 3,181 | $21K | |
| 91322 | <1% | 427 | $20K | |
| 90837 | Psychotherapy session, about an hour | <1% | 247 | $20K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 553 | $20K |
| 76818 | <1% | 1,728 | $20K | |
| 80306 | <1% | 1,125 | $20K | |
| 90698 | <1% | 3,370 | $20K | |
| 11102 | <1% | 180 | $19K | |
| 80069 | <1% | 1,586 | $19K | |
| 73502 | <1% | 1,808 | $19K | |
| 93017 | <1% | 804 | $19K | |
| 96101 | <1% | 117 | $19K | |
| 87653 | <1% | 290 | $18K | |
| 91065 | <1% | 348 | $18K | |
| 93226 | <1% | 874 | $17K | |
| 95819 | <1% | 141 | $17K | |
| 85730 | <1% | 3,378 | $17K | |
| 86618 | <1% | 834 | $17K | |
| 80164 | <1% | 268 | $16K | |
| 83540 | <1% | 3,766 | $16K | |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 87 | $16K |
| 84402 | <1% | 450 | $16K | |
| 82150 | <1% | 3,209 | $16K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 712 | $15K |
| 96367 | <1% | 297 | $15K | |
| 88720 | <1% | 265 | $15K | |
| 73590 | <1% | 971 | $15K | |
| 72082 | <1% | 563 | $15K | |
| 90744 | <1% | 1,795 | $14K | |
| 64483 | <1% | 102 | $14K | |
| 94060 | <1% | 996 | $14K | |
| 85652 | <1% | 6,665 | $14K | |
| D0330 | Panoramic radiographic image | <1% | 166 | $14K |
| G0506 | Comprehensive assessment of and care planning for patients requiring chronic care management services (list separately in addition to primary monthly care management service) | <1% | 12 | $14K |
| 29405 | <1% | 113 | $13K | |
| 73030 | <1% | 2,557 | $13K | |
| 31575 | <1% | 223 | $13K | |
| 86038 | <1% | 1,242 | $13K | |
| 76536 | <1% | 311 | $13K | |
| 90688 | <1% | 725 | $12K | |
| 92134 | <1% | 3,225 | $12K | |
| 84146 | <1% | 215 | $12K | |
| 96137 | <1% | 155 | $12K | |
| 90696 | <1% | 962 | $12K | |
| 82043 | <1% | 2,335 | $12K | |
| 99385 | <1% | 205 | $12K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 92 | $12K |
| 80076 | <1% | 653 | $12K | |
| 92567 | <1% | 501 | $12K | |
| 86900 | <1% | 4,278 | $11K | |
| 73562 | <1% | 2,459 | $11K | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 26 | $11K |
| 90714 | <1% | 468 | $11K | |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg | <1% | 50 | $11K |
| 86706 | <1% | 1,322 | $11K | |
| 93922 | <1% | 883 | $10K | |
| J9035 | Injection, bevacizumab, 10 mg | <1% | 66 | $10K |
| 86704 | <1% | 996 | $10K | |
| 92083 | <1% | 733 | $10K | |
| 87102 | <1% | 1,110 | $10K | |
| G0008 | Administration of influenza virus vaccine | <1% | 5,919 | $9K |
| 87205 | <1% | 3,779 | $9K | |
| 84460 | <1% | 2,224 | $9K | |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | <1% | 1,875 | $9K |
| 82746 | <1% | 864 | $9K | |
| 86901 | <1% | 4,202 | $9K | |
| D7240 | Removal of impacted tooth - completely bony | <1% | 16 | $9K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 11,107 | $9K |
| 84450 | <1% | 1,601 | $8K | |
| 87480 | <1% | 207 | $8K | |
| 86480 | <1% | 135 | $8K | |
| 82947 | <1% | 1,745 | $8K | |
| 73560 | <1% | 693 | $8K | |
| 51702 | <1% | 442 | $8K | |
| 83993 | <1% | 264 | $8K | |
| 84100 | <1% | 1,896 | $8K | |
| 72100 | <1% | 1,608 | $7K | |
| 73130 | <1% | 1,960 | $7K | |
| 93297 | <1% | 280 | $7K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,314 | $7K |
| 76642 | <1% | 274 | $7K | |
| 72170 | <1% | 444 | $7K | |
| 87505 | <1% | 72 | $7K | |
| 93308 | <1% | 71 | $7K | |
| 84156 | <1% | 2,382 | $7K | |
| 93351 | <1% | 58 | $7K | |
| 92557 | <1% | 390 | $7K | |
| 0001A | <1% | 343 | $7K | |
| 82550 | <1% | 1,061 | $7K | |
| 90707 | <1% | 1,194 | $6K | |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 166 | $6K |
| 82247 | <1% | 922 | $6K | |
| 88342 | <1% | 2,056 | $6K | |
| 84132 | <1% | 1,119 | $6K | |
| 76942 | <1% | 1,173 | $6K | |
| 95886 | <1% | 102 | $6K | |
| 0002A | <1% | 322 | $6K | |
| 87493 | <1% | 247 | $6K | |
| 64495 | <1% | 41 | $6K | |
| 83001 | <1% | 336 | $6K | |
| 70355 | <1% | 265 | $6K | |
| 82977 | <1% | 714 | $5K | |
| 92579 | <1% | 137 | $5K | |
| 94664 | <1% | 437 | $5K | |
| 86376 | <1% | 193 | $5K | |
| 83615 | <1% | 1,620 | $5K | |
| 84295 | <1% | 1,230 | $5K | |
| 73110 | <1% | 1,201 | $5K | |
| 87468 | <1% | 170 | $5K | |
| 90480 | <1% | 304 | $5K | |
| 95816 | <1% | 39 | $5K | |
| 73090 | <1% | 377 | $5K | |
| 86003 | <1% | 107 | $5K | |
| 76937 | <1% | 785 | $5K | |
| 93970 | <1% | 155 | $5K | |
| 51798 | <1% | 2,126 | $5K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,698 | $5K |
| 96376 | <1% | 6,189 | $5K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 214 | $5K |
| 87660 | <1% | 206 | $5K | |
| 85049 | <1% | 936 | $5K | |
| 77080 | <1% | 171 | $5K | |
| 87510 | <1% | 213 | $4K | |
| 87469 | <1% | 170 | $4K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 127 | $4K |
| 90710 | <1% | 1,043 | $4K | |
| 72040 | <1% | 546 | $4K | |
| 87484 | <1% | 170 | $4K | |
| 82670 | <1% | 174 | $4K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 123 | $4K |
| 84481 | <1% | 194 | $4K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 313 | $4K |
| 84403 | <1% | 115 | $4K | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 306 | $4K |
| C9257 | Injection, bevacizumab, 0.25 mg | <1% | 29 | $4K |
| 36415 | Collection of venous blood by venipuncture | <1% | 93,627 | $4K |
| 82077 | <1% | 423 | $4K | |
| 58300 | <1% | 67 | $4K | |
| 73564 | <1% | 695 | $4K | |
| 52000 | <1% | 14 | $3K | |
| 12001 | <1% | 39 | $3K | |
| 86200 | <1% | 233 | $3K | |
| 87176 | <1% | 1,272 | $3K | |
| 71045 | Radiologic examination, chest; single view | <1% | 3,941 | $3K |
| 94729 | <1% | 787 | $3K | |
| G0127 | Trimming of dystrophic nails, any number | <1% | 218 | $3K |
| 0004A | <1% | 59 | $3K | |
| 11750 | <1% | 26 | $3K | |
| 84550 | <1% | 691 | $3K | |
| 95700 | <1% | 18 | $3K | |
| 71250 | <1% | 92 | $3K | |
| 74230 | <1% | 38 | $3K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 100 | $3K |
| 99401 | <1% | 61 | $3K | |
| 59426 | <1% | 28 | $2K | |
| 73522 | <1% | 102 | $2K | |
| 73080 | <1% | 256 | $2K | |
| 86709 | <1% | 224 | $2K | |
| 62323 | <1% | 12 | $2K | |
| 86231 | <1% | 262 | $2K | |
| 82785 | <1% | 178 | $2K | |
| 73140 | <1% | 481 | $2K | |
| 88304 | <1% | 1,105 | $2K | |
| 73070 | <1% | 107 | $2K | |
| 85007 | <1% | 647 | $2K | |
| 77002 | <1% | 154 | $2K | |
| 64642 | <1% | 14 | $2K | |
| 86481 | <1% | 34 | $2K | |
| 90381 | <1% | 37 | $2K | |
| 86431 | <1% | 496 | $2K | |
| 73552 | <1% | 202 | $2K | |
| 70486 | <1% | 56 | $2K | |
| 84630 | <1% | 132 | $2K | |
| 95812 | <1% | 17 | $2K | |
| 43235 | <1% | 13 | $2K | |
| 90661 | <1% | 288 | $2K | |
| 87209 | <1% | 12 | $2K | |
| 77072 | <1% | 158 | $2K | |
| 36591 | <1% | 1,037 | $2K | |
| 59425 | <1% | 17 | $2K | |
| 86160 | <1% | 152 | $2K | |
| 99402 | <1% | 57 | $2K | |
| J0475 | Injection, baclofen, 10 mg | <1% | 13 | $2K |
| 94726 | <1% | 399 | $2K | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 288 | $2K |
| 92133 | <1% | 879 | $2K | |
| 81003 | <1% | 202 | $2K | |
| 73100 | <1% | 49 | $2K | |
| 83002 | <1% | 126 | $2K | |
| 11100 | <1% | 15 | $2K | |
| 97803 | <1% | 955 | $2K | |
| 90656 | <1% | 301 | $2K | |
| 82951 | <1% | 16 | $2K | |
| 96156 | <1% | 29 | $2K | |
| 92556 | <1% | 16 | $2K | |
| 87529 | <1% | 26 | $2K | |
| 73120 | <1% | 288 | $2K | |
| 90380 | <1% | 75 | $2K | |
| 90677 | <1% | 647 | $1K | |
| 36592 | <1% | 7,112 | $1K | |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | <1% | 1,220 | $1K |
| 82533 | <1% | 59 | $1K | |
| 99241 | <1% | 33 | $1K | |
| 89051 | <1% | 81 | $1K | |
| 87106 | <1% | 36 | $1K | |
| 72141 | <1% | 18 | $1K | |
| 73620 | <1% | 91 | $1K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 88 | $1K |
| 83718 | <1% | 40 | $1K | |
| 93990 | <1% | 59 | $1K | |
| 90662 | <1% | 360 | $990.02 | |
| J2777 | Injection, faricimab-svoa, 0.1 mg | <1% | 18 | $983.07 |
| 93880 | <1% | 73 | $939.82 | |
| 80197 | <1% | 29 | $931.43 | |
| 11981 | <1% | 16 | $849.84 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 129 | $810.63 |
| 80177 | <1% | 46 | $776.26 | |
| 95909 | <1% | 17 | $744.95 | |
| 96158 | <1% | 31 | $739.29 | |
| 82310 | <1% | 172 | $734.41 | |
| 84134 | <1% | 176 | $714.50 | |
| 87147 | <1% | 194 | $713.08 | |
| 90697 | <1% | 917 | $692.08 | |
| 76820 | <1% | 86 | $658.84 | |
| 93660 | <1% | 13 | $596.58 | |
| 97162 | <1% | 155 | $585.69 | |
| 97161 | <1% | 119 | $579.34 | |
| 93926 | <1% | 18 | $555.72 | |
| 94375 | <1% | 58 | $546.84 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 97 | $522.68 |
| 96116 | <1% | 14 | $508.52 | |
| 0031A | <1% | 23 | $470.44 | |
| 84165 | <1% | 70 | $465.17 | |
| 76882 | <1% | 14 | $461.91 | |
| 93225 | <1% | 92 | $455.26 | |
| 88307 | <1% | 159 | $442.55 | |
| J8501 | Aprepitant, oral, 5 mg | <1% | 75 | $440.62 |
| 90750 | <1% | 186 | $411.15 | |
| 0011A | <1% | 37 | $397.72 | |
| G0476 | Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test | <1% | 348 | $396.73 |
| 94762 | <1% | 70 | $387.57 | |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | <1% | 187 | $383.20 |
| 86880 | <1% | 26 | $355.57 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 184 | $352.50 |
| 82330 | <1% | 36 | $345.34 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 171 | $326.11 |
| 82465 | <1% | 71 | $325.06 | |
| 83520 | <1% | 15 | $319.76 | |
| 82378 | <1% | 15 | $318.13 | |
| 90678 | <1% | 38 | $307.06 | |
| 0012A | <1% | 20 | $295.48 | |
| 73700 | <1% | 13 | $294.66 | |
| 91321 | <1% | 87 | $280.59 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 10,716 | $262.18 |
| 97165 | <1% | 44 | $247.95 | |
| 90687 | <1% | 39 | $231.49 | |
| 82610 | <1% | 16 | $231.04 | |
| 93271 | <1% | 14 | $201.90 | |
| 86255 | <1% | 16 | $199.84 | |
| 97802 | <1% | 96 | $181.07 | |
| 76813 | <1% | 26 | $179.80 | |
| 82040 | <1% | 50 | $177.67 | |
| 76825 | <1% | 16 | $173.89 | |
| 17000 | <1% | 12 | $173.64 | |
| 87185 | <1% | 47 | $161.25 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 714 | $160.62 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,015 | $156.20 |
| 93280 | <1% | 18 | $145.48 | |
| 86225 | <1% | 12 | $144.80 | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 49 | $143.61 |
| 84520 | <1% | 46 | $136.78 | |
| 83525 | <1% | 12 | $134.01 | |
| 0124A | <1% | 218 | $132.64 | |
| 88341 | <1% | 79 | $125.38 | |
| 86705 | <1% | 26 | $122.08 | |
| 87177 | <1% | 12 | $110.58 | |
| 99386 | <1% | 19 | $96.70 | |
| 87206 | <1% | 18 | $95.68 | |
| C1769 | Guide wire | <1% | 3,330 | $93.94 |
| 99153 | Mod sedat endo service >5yrs | <1% | 353 | $93.29 |
| 90732 | <1% | 21 | $93.24 | |
| 76827 | <1% | 16 | $91.11 | |
| 86308 | <1% | 13 | $87.40 | |
| 82010 | <1% | 15 | $85.76 | |
| 0072A | <1% | 61 | $67.56 | |
| 74019 | <1% | 123 | $67.36 | |
| 99354 | <1% | 460 | $65.31 | |
| 87207 | <1% | 25 | $61.90 | |
| J3490 | Unclassified drugs | <1% | 6,177 | $55.75 |
| 88312 | <1% | 36 | $47.96 | |
| Q2039 | Influenza virus vaccine, not otherwise specified | <1% | 15 | $46.62 |
| 99152 | <1% | 206 | $37.11 | |
| 87210 | <1% | 14 | $36.48 | |
| 99151 | <1% | 70 | $31.48 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 8,779 | $29.06 |
| J2704 | Injection, propofol, 10 mg | <1% | 11,643 | $28.10 |
| 0071A | <1% | 40 | $27.24 | |
| J1815 | Injection, insulin, per 5 units | <1% | 2,657 | $20.72 |
| 73600 | <1% | 16 | $20.27 | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 5,975 | $14.85 |
| G0009 | Administration of pneumococcal vaccine | <1% | 226 | $14.10 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 465 | $12.82 |
| 36416 | <1% | 510 | $12.54 | |
| 88112 | <1% | 14 | $12.33 | |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 499 | $5.75 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 14,338 | $3.97 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 19,036 | $3.72 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 8,341 | $3.70 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 752 | $3.51 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 2,676 | $3.41 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 3,274 | $2.81 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 162 | $1.99 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 1,223 | $1.96 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 4,159 | $1.59 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 10,939 | $1.46 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 13,646 | $1.19 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 839 | $0.67 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 5,169 | $0.52 |
| Q0112 | All potassium hydroxide (koh) preparations | <1% | 18 | $0.52 |
| C1758 | Catheter, ureteral | <1% | 108 | $0.50 |
| J3535 | Drug administered through a metered dose inhaler | <1% | 659 | $0.35 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,147 | $0.32 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 5,428 | $0.11 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 852 | $0.08 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 504 | $0.05 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 828 | $0.04 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 1,405 | $0.03 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 2,232 | $0.01 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 1,234 | $0.01 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | 0% | 1,478 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 856 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 249 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 895 | $0.00 |
| 96411 | 0% | 26 | $0.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 1,353 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 1,084 | $0.00 |
| A9270 | Non-covered item or service | 0% | 7,613 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 1,886 | $0.00 |
| J0461 | Injection, atropine sulfate, 0.01 mg | 0% | 396 | $0.00 |
| 94761 | 0% | 979 | $0.00 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 704 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 66 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 657 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 199 | $0.00 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 296 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 1,444 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 16 | $0.00 |
| C1755 | Catheter, intraspinal | 0% | 294 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 181 | $0.00 |
| D9223 | Deep sedation/general anesthesia - each subsequent 15 minute increment | 0% | 13 | $0.00 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | 0% | 405 | $0.00 |
| 72072 | 0% | 12 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 48 | $0.00 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 113 | $0.00 |
| 96409 | 0% | 145 | $0.00 | |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 200 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 107 | $0.00 |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | 0% | 50 | $0.00 |
| A7037 | Tubing used with positive airway pressure device | 0% | 30 | $0.00 |
| 96154 | 0% | 19 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 203 | $0.00 |
| 3044F | 0% | 32 | $0.00 | |
| L8699 | Prosthetic implant, not otherwise specified | 0% | 16 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 12 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 78 | $0.00 |
| 0081A | 0% | 20 | $0.00 | |
| D9222 | 0% | 19 | $0.00 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 816 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 919 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 4,244 | $0.00 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 0% | 17 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 150 | $0.00 |
| A9578 | Injection, gadobenate dimeglumine (multihance multipack), per ml | 0% | 985 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 780 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 373 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 1,377 | $0.00 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 1,396 | $0.00 |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | 0% | 2,017 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 209 | $0.00 |
| C1729 | Catheter, drainage | 0% | 76 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 366 | $0.00 |
| A7038 | Filter, disposable, used with positive airway pressure device | 0% | 62 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 320 | $0.00 |
| J7070 | Infusion, d5w, 1000 cc | 0% | 197 | $0.00 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | 0% | 190 | $0.00 |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | 0% | 55 | $0.00 |
| Q4133 | Grafix prime, grafixpl prime, stravix and stravixpl, per square centimeter (add-on, list separately in addition to primary procedure) | 0% | 91 | $0.00 |
| Q4038 | Cast supplies, short leg cast, adult (11 years +), fiberglass | 0% | 47 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 552 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 125 | $0.00 |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or qualified healthcare professional, with or without direct patient contact (list separately in addition to cpt codes 99205, 99215, 99483 for office or other outpatient evaluation and management services) (do not report g2212 on the same date of service as 99358, 99359, 99415, 99416). (do not report g2212 for any time unit less than 15 minutes) | 0% | 183 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 110 | $0.00 |
| A7031 | Face mask interface, replacement for full face mask, each | 0% | 48 | $0.00 |
| 99199 | Unlisted special service, procedure or report | 0% | 36 | $0.00 |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 31 | $0.00 |
| V5266 | Battery for use in hearing device | 0% | 42 | $0.00 |
| 36600 | 0% | 18 | $0.00 | |
| 90785 | 0% | 121 | $0.00 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 184 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 53 | $0.00 |
| 77003 | 0% | 13 | $0.00 | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 15 | $0.00 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | 0% | 43 | $0.00 |
| A7035 | Headgear used with positive airway pressure device | 0% | 15 | $0.00 |
| 72110 | 0% | 15 | $0.00 | |
| J1756 | Injection, iron sucrose, 1 mg | 0% | 40 | $0.00 |
| J7643 | Glycopyrrolate, inhalation solution, compounded product, administered through dme, unit dose form, per milligram | 0% | 22 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMUNSON, JOLYN (VP REVENUE CYCLE OPERATIONS)
Parent organizationMARSHFIELD CLINIC HEALTH SYSTEM INC
| Provider | Location | Paid |
|---|---|---|
| Marshfield Clinic INC | Marshfield, WI | $19.61M |
| MCHS Hospitals INC | Eau Claire, WI | $12.41M |
| MCHS Hospitals INC | Marshfield, WI | $11.82M |
| Beaver Dam Community Hospitals INC | Beaver Dam, WI | $10.58M |
| Dickinson County Healthcare System | Iron Mountain, MI | $10.23M |
| MCHS Hospitals INC | Ladysmith, WI | $7.36M |
| MCHS Hospitals INC | Weston, WI | $6.40M |
| MCHS Hospitals INC | Eau Claire, WI | $4.14M |
| MCHS Hospitals INC | Minocqua, WI | $2.90M |
| Dickinson County Healthcare System | Iron Mountain, MI | $2.44M |
| Dickinson County Healthcare System | Iron Mountain, MI | $2.29M |
| MCHS Hospitals INC | Wausau, WI | $1.84M |
| MCHS Hospitals INC | Weston, WI | $1.22M |
| MCHS Hospitals INC | Minocqua, WI | $1.16M |
| MCHS Hospitals INC | Marshfield, WI | $988K |
| MCHS Hospitals INC | Ladysmith, WI | $867K |
| Beaver Dam Community Hospitals INC | Beaver Dam, WI | $847K |
| Dickinson County Healthcare System | Iron Mountain, MI | $648K |
| MCHS Hospitals INC | Marshfield, WI | $563K |
| MCHS Hospitals INC | Minocqua, WI | $338K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.